Nasdaq · CIK 0001420565
RNTX Rein Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing May 28, 2026. Close $0.79 on Oct 9, 2026, +13% from the 52-week low and -58% from the high.
Rein Therapeutics, Inc. (RNTX) has 16 SEC Form 4 filings on file from 7 insiders, the latest filed on May 28, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
5 open-market trades have been scored at RNTX. The newest: Josef H Von Rickenbach (director) bought $50k of stock on May 21, 2026, filed May 28, 2026, scored 50 (moderate). The largest of the 5 shown: Voss Capital, LP (10% owner) bought $423k on Oct 24, 2025, scored 29 (weak).
RNTX closed at $0.79 on Oct 9, 2026, 13% above its 52-week low and 58% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Rein Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Josef H Von Rickenbach director buy | $50k 47,060 shares | +305% | +7% from low-49% from high | |
| 38Weak | James Brian Windsor See Remarks buy | $25k 25,000 shares | +1222% | +27% from low-43% from high | |
| 26Weak | Voss Capital, LP owner buy | $128k 104,183 shares | +13% | - | |
| 29Weak | Voss Capital, LP owner buy | $423k 306,050 shares | +44% | - | |
| 33Weak | James Brian Windsor President and CEO buy | $898 400 shares | - | - |
Transactions
Every row filed, 24 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | Josef H Von Rickenbach director | POpen-market purchase Common stock , $0.001 par value | +3,420 | $1.04 | $3,564 | 18,874 | May 28, 2026 |
| May 22, 2026 | Josef H Von Rickenbach director | POpen-market purchase Common stock , $0.001 par value | +15,950 | $1.05 | $17k | 34,824 | May 28, 2026 |
| May 26, 2026 | Josef H Von Rickenbach director | POpen-market purchase Common stock , $0.001 par value | +23,190 | $1.06 | $24k | 58,014 | May 28, 2026 |
| May 27, 2026 | Josef H Von Rickenbach director | POpen-market purchase Common stock , $0.001 par value | +4,500 | $1.07 | $4,819 | 62,514 | May 28, 2026 |
| Apr 30, 2026 | James Brian Windsor See Remarks | POpen-market purchase Common stock , $0.001 par value | +25,000 | $1.00 | $25k | 27,046 | May 13, 2026 |
| May 8, 2026 | James Brian Windsor See Remarks | AGrant or award Stock Option (Right to Buy)derivative | -150,000 | $0.00 | $0 | 150,000 | May 13, 2026 |
| Nov 14, 2025 | Voss Capital, LP owner | POpen-market purchase Common Stock, $0.001 par valueindirect: By: Voss Value Master Fund, L.P. | +104,183 | $1.22 | $128k | 926,441 | Nov 18, 2025 |
| Oct 24, 2025 | Voss Capital, LP owner | POpen-market purchase Common Stock, $0.001 par valueindirect: By: Voss Value Master Fund, L.P. | +30,176 | $1.39 | $42k | 729,616 | Oct 28, 2025 |
| Oct 27, 2025 | Voss Capital, LP owner | POpen-market purchase Common Stock, $0.001 par valueindirect: By: Voss Value Master Fund, L.P. | +92,642 | $1.37 | $127k | 822,258 | Oct 28, 2025 |
| Oct 27, 2025 | Voss Capital, LP owner | POpen-market purchase Common Stock, $0.001 par valueindirect: By: Voss Value-Oriented Special Situations Fund, L.P. | +4,840 | $1.37 | $6,625 | 321,608 | Oct 28, 2025 |
| Oct 28, 2025 | Voss Capital, LP owner | POpen-market purchase Common Stock, $0.001 par valueindirect: By: Voss Value-Oriented Special Situations Fund, L.P. | +178,392 | $1.39 | $248k | 500,000 | Oct 28, 2025 |
| Jul 23, 2025 | Reinhard J. Ambros director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jul 23, 2025 |
| Jul 23, 2025 | Josef H Von Rickenbach director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jul 23, 2025 |
| Jul 23, 2025 | Alan A Musso director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jul 23, 2025 |
| Jul 23, 2025 | William Fairey director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jul 23, 2025 |
| Jul 23, 2025 | Manuel Aivado director | AGrant or award Stock Option (right to buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Jul 23, 2025 |
| Dec 5, 2024 | James Brian Windsor President and CEO | POpen-market purchase Common Stockindirect: By son | +239 | $2.24 | $535 | 239 | Dec 9, 2024 |
| Dec 5, 2024 | James Brian Windsor President and CEO | POpen-market purchase Common Stockindirect: By son | +161 | $2.25 | $362 | 161 | Dec 9, 2024 |
| Dec 2, 2024 | Alan A Musso director | AGrant or award Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Dec 6, 2024 |
| Dec 2, 2024 | Josef H Von Rickenbach director | AGrant or award Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Dec 6, 2024 |
| Dec 2, 2024 | William Fairey director | AGrant or award Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Dec 6, 2024 |
| Dec 2, 2024 | Reinhard J. Ambros director | AGrant or award Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Dec 6, 2024 |
| Dec 2, 2024 | Manuel Aivado director | AGrant or award Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Dec 6, 2024 |
| Dec 2, 2024 | James Brian Windsor President and CEO | AGrant or award Stock Option (right to buy)derivative | +517,500 | $0.00 | $0 | 517,500 | Dec 4, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Manuel Aivadodirector
- Reinhard J. Ambrosdirector
- William Faireydirector
- Alan A Mussodirector, cfo, officer
- Josef H Von Rickenbachdirector
- Voss Capital, LPowner
- James Brian WindsorSee Remarks
Questions about RNTX
Answered from the filings on this page, as of the latest one.
Are insiders buying RNTX?
No. In the last 90 days no insider at Rein Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RNTX on the open market?
Josef H Von Rickenbach (director) bought $50k of RNTX on May 21, 2026 and filed the Form 4 on May 28, 2026. InsiderTell scored 50 (moderate).
How many insiders file Form 4 at Rein Therapeutics, Inc.?
7 people have filed a Form 4 at Rein Therapeutics, Inc., among them Manuel Aivado (director), Reinhard J. Ambros (director), William Fairey (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.